Increased tissue arginase enzyme activity and ornithine
levels together appear to enlarge in polyamine formation, which would lead to cancer development.
2] partial pressure; IEM, inborn error of metabolism; OTC, ornithine
transcarbamylase; CVVH, continuous venovenous hemofiltration.
Plasma amino acid analysis revealed absence of citrulline and argininosuccinic acid, low normal ornithine
, and high urinary orotic acid levels consistent with proximal urea cycle defects like Ornithine
Transcarbamylase deficiency (OTC), N-acetyl Glutamate Synthase deficiency (NAGS), and Carbomyl Phosphate Synthase 1 deficiency (CPS1).
In-creased frequency of spontaneous skin tumors in transgenic mice which over-express ornithine
Four of the seven identified metabolites--histidine, arginine, ornithine
and glutamine--are related to genes involved in arginine-glutamine metabolism and nitrogen compound biosynthesis.
Tamir and Ratner (1963) attributed birds' incapacity to synthesize ornithine
, citrulline and Arg to the absence of another enzyme key to the urea cycle, ornithine
carbamoyltransferase (Figure 2).
Measurement of OAT activity: The activity of ornithine
aminotransferase (OAT) was determined as described by Wu et al.
It is important to mention that because the Lowry method to determine the protein concentration does not measure fibrous proteins like collagen and elastin, proteins synthesized during the tissue healing process, and it is known that diabetes causes damage to the microvasculature [41, 42] and that ornithine
, a product derived from arginine hydrolysis, can be used to synthetize proline, an amino acid needed for collagen synthesis, we decided to express the concentration of biomolecules related to dry weight.
Compelling evidence demonstrates that the combination of arginine and ornithine
augments the results of resistance training by helping to increase lean body mass and strength.
Many studies have shown that ornithine
decarboxylase (ODC; EC 4.
professor of medicine and biological chemistry at the University of California, Irvine, presented "late-breaking" results from a phase III trial of difluoromethylornithine (DFMO), a synthetic inhibitor of ornithine
decarboxylase, and sulindac (Clinoril), a nonsteroidal, anti-inflammatory drug (NSAID), in 375 patients.
The enzymatic activity of ornithine
decarboxylase (ODC), which is one of the limiting enzymes of PAs biosynthesis, is not well regulated in can cer cells, participating in the transformation of cell phenotype from normal to malignant (Babbar and Gerner, 2003).